Status:
UNKNOWN
The Incidence of Infection in Treatment of Low-dose IL-2 of SLE Patients
Lead Sponsor:
Peking University People's Hospital
Conditions:
Infection
Eligibility:
All Genders
18-80 years
Brief Summary
IL-2 is a pleiotropic cytokine which can regulate or stimulate the differentiation and function of CD4+, CD8+ and NK cells. An opened-labelled trial and a retrospective study have indicated the incide...
Detailed Description
We are going to conduct a multi-center prospective observational study, and plan to enroll 500 SLE patients. Low-dose IL-2 is defined as 100IU IL-2 injected subcutaneously every other day for two week...
Eligibility Criteria
Inclusion
- SLE patients diagnosed by the ACR Criteria of 1987;
- Treated with low-dose IL-2, corticosteroid and immunosuppressor for SLE.
- Consent to participate in this study.
- Regular follow-up for at least 2 years.
Exclusion
- Other autoimmune disease;
- Without treatment of low-dose IL-2, corticosteroid and immunosuppressor for SLE.
- Mental disorder without regular or specific treatment.
Key Trial Info
Start Date :
July 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 30 2021
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04136106
Start Date
July 1 2019
End Date
December 30 2021
Last Update
October 23 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking Universtiy People's Hospital
Beijing, Beijing Municipality, China, 100044